Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
Marta Seghieri, Alexander S. Christensen, Andreas Andersen, et al.
Frontiers in Endocrinology (2018) Vol. 9
Open Access | Times Cited: 79

Showing 26-50 of 79 citing articles:

Thioredoxin/Glutaredoxin Systems and Gut Microbiota in NAFLD: Interplay, Mechanism, and Therapeutical Potential
Minghui Zhu, Omer M. A. Dagah, Billton Bryson Silaa, et al.
Antioxidants (2023) Vol. 12, Iss. 9, pp. 1680-1680
Open Access | Times Cited: 19
Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway
Xue Han, Chuan‐Hua Ding, Guangdong Zhang, et al.
Biochemical and Biophysical Research Communications (2020) Vol. 525, Iss. 4, pp. 895-901
Closed Access | Times Cited: 49
Renin–Angiotensin System in Liver Metabolism: Gender Differences and Role of Incretins
Zainab Mastoor, Yolanda Diz-Chaves, Lucas C. González-Matías, et al.
Metabolites (2022) Vol. 12, Iss. 5, pp. 411-411
Open Access | Times Cited: 24
Incretin combination therapy for the treatment of non‐alcoholic steatohepatitis
Aimo Kannt, Andreas Nygaard Madsen, Claire Kammermeier, et al.
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 8, pp. 1328-1338
Open Access | Times Cited: 34
Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment
Bo Zhu, Siu‐Lung Chan, Jack Li, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 32
Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis
Yuzhao Dai, He He, Sheyu Li, et al.
Frontiers in Endocrinology (2021) Vol. 11
Open Access | Times Cited: 28
The Effect of Bioactive Aliment Compounds and Micronutrients on Non-Alcoholic Fatty Liver Disease
Camelia Munteanu, Betty Schwartz
Antioxidants (2023) Vol. 12, Iss. 4, pp. 903-903
Open Access | Times Cited: 13
Ferulic acid reduces GLP‐1 degradation to ameliorate diet‐induced obesity‐associated hepatic steatosis
Yuxuan An, Lichao Zhang, Xiaxia Fan, et al.
Food Frontiers (2024) Vol. 5, Iss. 2, pp. 691-707
Open Access | Times Cited: 4
Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes Mellitus
Asif Ali, Peter R. Flatt, Nigel Irwin
Clinical Medicine Insights Endocrinology and Diabetes (2024) Vol. 17
Open Access | Times Cited: 4
SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity
Hikaru Ueno, Ryo Ito, Shinichi Abe, et al.
Journal of Pharmacology and Experimental Therapeutics (2019) Vol. 370, Iss. 2, pp. 172-181
Open Access | Times Cited: 35
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Kerstin Stemmer, Brian Finan, Richard D. DiMarchi, et al.
Advanced Drug Delivery Reviews (2020) Vol. 159, pp. 34-53
Closed Access | Times Cited: 32
Resveratrol Reduces Glucolipid Metabolic Dysfunction and Learning and Memory Impairment in a NAFLD Rat Model: Involvement in Regulating the Imbalance of Nesfatin-1 Abundance and Copine 6 Expression
Xing‐Xing Chen, Yayun Xu, Rui Wu, et al.
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 30
Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity
Zhihong Yao, Wang Chen, Zhu Qianqian, et al.
Peptides (2023) Vol. 162, pp. 170955-170955
Closed Access | Times Cited: 10
The developmental trajectory of GLP-1 receptor agonists
Binbin Kou, Hai Qian
Elsevier eBooks (2025), pp. 41-54
Closed Access
Liraglutide ameliorates lipotoxicity-induced inflammation through the mTORC1 signalling pathway
Na Ao, Zhuoqi Ma, Jing Yang, et al.
Peptides (2020) Vol. 133, pp. 170375-170375
Closed Access | Times Cited: 25
The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror
María Sofía Martínez, Alexander Manzano, Luis Carlos Olivar, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9504-9504
Open Access | Times Cited: 21
The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight
Mitsugi Ookawara, Keisuke Matsuda, Masanori Watanabe, et al.
Journal of Pharmacology and Experimental Therapeutics (2020) Vol. 375, Iss. 1, pp. 21-27
Open Access | Times Cited: 22
Anti-inflammatory effects of GLP-1 in patients with COVID-19
Saharnaz Sazgarnejad, Niloufar Yazdanpanah, Nima Rezaei
Expert Review of Anti-infective Therapy (2021) Vol. 20, Iss. 3, pp. 373-381
Open Access | Times Cited: 19
Fatty kidney: A possible future for chronic kidney disease research
Mehmet Kanbay, Sidar Çöpür, Atalay Demiray, et al.
European Journal of Clinical Investigation (2022) Vol. 52, Iss. 6
Closed Access | Times Cited: 14
Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—Current Background, Hopes, and Perspectives
Georgiana-Diana Cazac, C.M. Lǎcǎtusu, Gabriela Ștefănescu, et al.
Metabolites (2023) Vol. 13, Iss. 5, pp. 581-581
Open Access | Times Cited: 7
Enhanced GIP Secretion in Obesity Is Associated with Biochemical Alteration and miRNA Contribution to the Development of Liver Steatosis
Joanna Góralska, Urszula Raźny, Anna Polus, et al.
Nutrients (2020) Vol. 12, Iss. 2, pp. 476-476
Open Access | Times Cited: 18
A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?
Rebecca Vincent, David M. Williams, Marc Evans
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 12, pp. 2227-2240
Open Access | Times Cited: 18
Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status
Sungho Bea, Han Eol Jeong, Kristian B. Filion, et al.
JAMA Network Open (2023) Vol. 6, Iss. 12, pp. e2349856-e2349856
Open Access | Times Cited: 6
Preventing Oxidative Stress in the Liver: An Opportunity for GLP-1 and/or PASK
Verónica Hurtado-Carneiro, Pilar Dongil, Ana Pérez-García, et al.
Antioxidants (2021) Vol. 10, Iss. 12, pp. 2028-2028
Open Access | Times Cited: 12
GPCRs get fatty: the role of G protein-coupled receptor signaling in the development and progression of nonalcoholic fatty liver disease
Ryan Kurtz, Meghan F. Anderman, Blythe D. Shepard
AJP Gastrointestinal and Liver Physiology (2020) Vol. 320, Iss. 3, pp. G304-G318
Open Access | Times Cited: 11

Scroll to top